.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Cipla
US Army
Harvard Business School
Queensland Health
Mallinckrodt
Healthtrust
Chinese Patent Office
Argus Health
Novartis

Generated: December 13, 2017

DrugPatentWatch Database Preview

TEFLARO Drug Profile

« Back to Dashboard

When do Teflaro patents expire, and what generic alternatives are available?

Teflaro is a drug marketed by Cerexa and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-six patent family members in thirty-two countries and ten supplementary protection certificates in nine countries.

The generic ingredient in TEFLARO is ceftaroline fosamil. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ceftaroline fosamil profile page.

Summary for TEFLARO

Drug patent expirations by year for TEFLARO

Pharmacology for TEFLARO

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
CerexaTEFLAROceftaroline fosamilPOWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
CerexaTEFLAROceftaroline fosamilPOWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
CerexaTEFLAROceftaroline fosamilPOWDER;IV (INFUSION)200327-002Oct 29, 2010RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
CerexaTEFLAROceftaroline fosamilPOWDER;IV (INFUSION)200327-002Oct 29, 2010RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
CerexaTEFLAROceftaroline fosamilPOWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
CerexaTEFLAROceftaroline fosamilPOWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
CerexaTEFLAROceftaroline fosamilPOWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
CerexaTEFLAROceftaroline fosamilPOWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
CerexaTEFLAROceftaroline fosamilPOWDER;IV (INFUSION)200327-002Oct 29, 2010RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
CerexaTEFLAROceftaroline fosamilPOWDER;IV (INFUSION)200327-002Oct 29, 2010RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for TEFLARO

Drugname Dosage Strength RLD Submissiondate
ceftaroline fosamilInjection400 mg/vial and 600 mg/vialTeflaro10/29/2014

International Patent Family for Tradename: TEFLARO

Country Document Number Estimated Expiration
Canada2314564► Subscribe
Canada2753387► Subscribe
South Korea100826487► Subscribe
World Intellectual Property Organization (WIPO)0214333► Subscribe
Austria431827► Subscribe
Canada2418614► Subscribe
Spain2325139► Subscribe
China1462275► Subscribe
New Zealand717866► Subscribe
Denmark1310502► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TEFLARO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2Finland► Subscribe
C0008France► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL, SES ESTERS OU SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/785/001 20120823
90003-0Sweden► SubscribePRODUCT NAME: CEFTAROLINFOSAMIL; REG. NO/DATE: EU/1/12/785/001 20120823
00568Netherlands► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/12/785/001 00120823
0568Netherlands► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/12/785/001 20120823
C/GB13/004United Kingdom► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/12/785/001 20120823
13/001Ireland► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/12/785/001 20120823
1043327/01Switzerland► SubscribePRODUCT NAME: CEFTAROLIN FOSAMIL; REGISTRATION NO/DATE: SWISSMEDIC 62672 29.08.2013
134Luxembourg► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (ZINFORO)
2013 00003Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Healthtrust
Argus Health
Accenture
Queensland Health
Teva
AstraZeneca
Fish and Richardson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot